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Abstract
Spinocerebellar ataxia type-3, also known as Machado-Joseph Disease (MJD), is one of many inherited neurodegenerative
disorders caused by polyglutamine-encoding CAG repeat expansions in otherwise unrelated genes. Disease protein
misfolding and aggregation, often within the nucleus of affected neurons, characterize polyglutamine disorders. Several
evidences have implicated the nucleus as the primary site of pathogenesis for MJD. However, the molecular determinants
for the nucleocytoplasmic transport of human ataxin-3 (Atx3), the protein which is mutated in patients with MJD, are not
characterized.
In order to characterize the nuclear shuttling activity of Atx3, we performed yeast nuclear import assays and found that Atx3
is actively imported into the nucleus, by means of a classical nuclear localizing sequence formed by a cluster of lysine and
arginine residues. On the other hand, when active nuclear export was inhibited using leptomycin B, a specific inhibitor of
the nuclear export receptor CRM1, both endogenous Atx3 and transfected GFP-Atx3 accumulated inside the nucleus of a
subpopulation of COS-7 cells, whereas both proteins are normally predominant in the cytoplasm.
Additionally, using a Rev(1.4)-GFP nuclear export assay, we performed an extensive analysis of six putative aliphatic nuclear
export motifs identified in Atx3 amino acid sequence. Although none of the tested peptide sequences were found to drive
nuclear export when isolated, we have successfully mapped the region of Atx3 responsible for its CRM1-independent
nuclear export activity. Curiously, the N-terminal Josephin domain alone is exported into the cytoplasm, but the nuclear
export activity of Atx3 is significantly enhanced in a longer construct that is truncated after the two ubiquitin interaction
motifs, upstream from the polyQ tract.
Our data show that Atx3 is actively imported to and exported from the cell nucleus, and that its nuclear export activity is
dependent on a motif located at its N-terminal region. Since pathological Atx3 aggregates in the nucleus of affected
neurons in MJD, and there is in vivo evidence that nuclear localization of Atx3 is required for the manifestation of symptoms
in MJD, defects in the nucleocytoplasmic shuttling activity of the protein may be involved in the nuclear accumulation and
aggregation of expanded Atx3.
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Introduction
Machado-Joseph disease (MJD), or spinocerebellar ataxia type
3, is the most common dominantly inherited ataxia worldwide and
it is caused by a polyglutamine (polyQ) expansion in ataxin-3
(Atx3), a polyubiquitin-binding protein [1] with ubiquitin protease
activity [2]. Full-length Atx3 contains an N-terminal Josephin
domain (JD), the conserved catalytic module, two ubiquitin
interacting motifs (UIMs), an expandable polyQ stretch, and a
short variable tail that might contain a third UIM depending on
the splice variant [3]. In normal individuals the size of the
polymorphic glutamine repeat can range between 14 and 40 while
in MJD patients the polyQ repeat is expanded to 53 or more
glutamines [4]. Human Atx3 is ubiquitously expressed and
displays a complex subcellular distribution involving both the
cytoplasm and the nucleus, depending on cell type [5,6,7]. Even
though its physiological role is still not clearly established, Atx3
was shown to be a cysteine protease with the ability to cleave
polyubiquitin chains with more than four ubiquitins, indepen-
dently of the polyglutamine tract [2]. This enzymatic activity of
Atx3 has been correlated with its ability to mitigate polyQ-induced
neurodegeneration in a Drosophila model [8], with its involvement
in aggresome formation [9] and in the degradation of misfolded
proteins [10]. Furthermore, it was also shown to bind to histones
[11] and to chromatin [12] indicating that Atx3 displays not only
cytoplasmic but also nuclear functions.
As for most other polyQ diseases, conformational changes
imparted by the expanded polyQ tract lead to the formation of
neuronal intranuclear inclusions (NIIs) [13] and may contribute to
pathogenesis by affecting gene expression [14] or by disrupting
nuclear organization and function [15]. In MJD patients specific
brain regions are affected such as the cerebellum and brainstem,
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[6,16,17]. It is becoming clear that although polyQ tracts
themselves are toxic, the sequence and structure of the proteins
carrying the polyQ tracts have important roles in defining the
course and specificity of the disease. Those sequences determine
subcellular localization, and specify interactions with other
macromolecules within the cell, strongly determining the differ-
ences in the specificity of neuronal degeneration characteristic of
polyQ disorders [18,19,20].
A contentious question has been whether polyQ-induced
pathogenesis is primarily activated in the cytoplasm or in the cell
nucleus. In fact predominantly nuclear inclusions have been found
in SCA1, SCA2, SCA7, SCA17, DRPLA, SBMA, and Hunting-
ton’s Disease (HD) patients [21], although cytoplasmic inclusions
have also been identified in affected brain regions in SCA2 [22]
and HD [23]. Evidence from HD transgenic mice shows that both
nuclear and cytoplasmic exon-1 huntingtin might contribute to
disease progression [23,24,25]. Nuclear environment has been
shown to favor toxicity, pathology and aggregation as evidenced
by nuclear targeting of polyQ peptides [26], even when inserted
into ectopic protein contexts [27].
Specific nuclear localization sequences (NLS) have been
identified in proteins carrying the expanded polyQ tracts, such
as ataxin-1 [28,29] and ataxin-7 [30], and nuclear-associated
mechanisms are being implicated in neuropathogenesis [13,31].
Similarly, nuclear export sequences (NES) have been found in
ataxin-7 [32] and huntingtin [33] and it was shown that polyQ
expansion impairs efficient nuclear export of these polyQ-
containing proteins [32,34].
Recently, it was demonstrated in vivo that adding an exogenous
NLS to Atx3(148Q) increases the severity of the phenotype and
induces earlier death in transgenic mouse models [35]. Accord-
ingly, adding an exogenous NES to Atx3(148Q) drives the
expanded protein out of the nucleus and prevents the manifesta-
tion of a phenotype [35]. This suggests that defects on the
nucleocytoplasmic shuttling activity of the expanded protein might
be correlated with pathology and neuronal specificity. Moreover,
in other transgenic models of Machado-Joseph disease there is
accumulation of the expanded Atx3 protein in the nucleus of
affected neurons [36,37,38]. However, the molecular determinants
for the nucleocytoplasmic transport of Atx3 are not characterized.
In order to gain further insights into the function of Atx3 and into
the disease-specific mechanisms of neurodegeneration in MJD, we
have set as our goal the identification of the determinants of Atx3
nucleocytoplasmic transport.
Nuclear targeting was analyzed in vivo using the yeast system
developed by Rhee et al. [39] and we found that Atx3 is actively
imported into the nucleus, by means of a classical NLS located in
its C-terminal region. Furthermore, using an in vivo nuclear export
assay we show that Atx3 is actively exported from the nucleus and
mapped this export activity to its N-terminal domain.
Methods
Yeast nuclear import assay
The yeast nuclear import assay was performed as described
previously [39]. The cDNA encoding the MJD1.a isoform of
ataxin-3 (AAB33571), containing 28 CAG repeats, was amplified
by PCR using the pEGFP-C1-ataxin-3(28Q) construct (kindly
provided by Dr. Henry Paulson) as template and using the primers
59tcccccgggcatggtgagcaagggcg39 and 59gcgtcgacttatgtcaga-
taaagtgtgaag39, which introduced SmaI and SalI recognition sites
at the 59 and 39 ends of the amplified DNA fragment, respectively.
The cDNA encoding ataxin-3(28Q) was cloned into the SmaI and
SalI sites of the plasmid for the yeast nuclear import assay (pNIA,
kindly provided by Vitaly Citovsky [39]), and named pNIA-GFP-
Atx3. The pNIA-GFP-Atx3R282T and pNIA-GFP-Atx3R282A
constructs were obtained by site-directed mutagenesis (Quick-
Change site-directed mutagenesis kit, Stratagene).
The pNIA constructs, encoding triple fusion proteins compris-
ing bacterial LexA, yeast Gal4p activation domain (Gal4AD), and
the tested protein, were transformed using the lithium acetate
method [40] into Saccharomyces cerevisiae L40 strain, which contains
the reporter genes HIS3 and lacZ with upstream LexA operators.
After transformation, yeasts were plated on selective medium
deficient for tryptophan, to select for transformed cells. Trans-
formed yeasts were then plated on selective medium lacking both
tryptophan and histidine, and supplemented with 100 mM 3-
amino-1,2,4-triazole (3AT; Sigma), an inhibitor of the His3p
enzyme, and growth was evaluated. Additionally, transformed
yeasts were grown in tryptophan-deficient liquid medium for
quantitative determination of b-galactosidase activity [41]. For the
enzymatic assay, cells were disrupted, and the b -galactosidase
substrate o-nitrophenyl-b-D-galactopyranoside (ONPG) was added
in excess. The reaction occurred at 30uC and was stopped by
raising the pH to 11. The optical density of the reaction product
was measured at 420 nm (OD420), and the b-galactosidase
activity was calculated according to the following equation:
bunits=1,0006OD420/t6V6OD600, where OD420 is the
optical density at 420 nm of the sample measured after the
incubation of yeast cell lysate with ONPG, t is the time of
incubation (in minutes) of the yeast cell lysate with ONPG, V is the
volume of the sample used in the assay (in milliliters), and OD600
is the optical density at 600 nm of the yeast cell culture at the start
of the assay.
Cell culture, transfection and leptomycin B treatment
HEK293 and COS-7 cells were grown and maintained in
Dulbecco’s modified Eagle’s medium-high glucose (DMEM-HG;
Sigma) supplemented with 10% (vol/vol) heat-inactivated fetal
bovine serum (FBS; Biochrom KG) and with 100 U of penicillin
and 100 mg of streptomycin (Sigma) per ml in a 5% CO2
humidified atmosphere at 37uC.
One day prior to transfection, COS-7 cells were seeded onto
glass coverslips on a 12-well plate, at a subconfluent density.
Transfection experiments were performed using Lipofectamine
reagent (Invitrogen) according to the manufacturer’s instructions,
using 1 mg of plasmid DNA per well. The cells were incubated for
48 hours to allow gene expression.
Where indicated, the cells were incubated with 20 ng/ml
leptomycin B (Sigma) in DMEM-HG supplemented with 10%
FBS for 3 hours prior to fixation.
Rev(1.4)-GFP nuclear export assay
To assess the strength of the nuclear export activity of different
fragments of Atx3 protein, or of full-length Atx3, the Rev(1.4)-GFP
nuclear export assay, described previously by Henderson and
Eleftheriou [42], was used. This assay is based on the
manipulation of the Rev protein shuttling cycle, and tests for the
ability of functional nuclear export sequences to promote the
nuclear export activity of the Rev(1.4)-GFP fusion protein, which
is composed of a NES-deficient mutant of the HIV-1 Rev protein
and GFP.
Potential Atx3 NES signals were identified by consensus to the
WX1–3WX2–3WXW motif (W indicates a large hydrophobic residue,
and X indicates any amino acid), and using the prediction
algorithm NetNES (http://www.cbs.dtu.dk/databases/NESbase-
1.0 [43]), and fused to Rev(1.4)-GFP fusion protein (the plasmid
Ataxin-3 Nuclear Shuttling
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Henderson). The putative sequences that were assayed include:
NES1, residues 76-SIQVISNALKVWGLELILF-94; NES2, 133-
LNSLLT-138; NES3, 142-LISDTYLALFLAQLQQE-158;
NES4, 174-ADQLLQMIRV-183; NES5, 209-LERVLE-214;
and NES6, 222-LDEDEEDLQRALALSRQEIDME-243. Fur-
thermore, full-length Atx3 (28Q and 84Q) or partial domains of
Atx3 (the Josephin domain and the domains comprising amino
acids 1–263 and 183–263) were also fused to Rev(1.4)-GFP fusion
protein.
COS-7 cells were transfected with pRev(1.4)-GFP (negative
control) or its derivative plasmids containing either the NES of the
HIV-1 Rev protein (positive control) or each of the sequences to be
tested. Forty-eight hours post-transfection, all cell samples were
treated with 10 mg/ml cycloheximide (CHX) to ensure that any
cytoplasmic GFP fluorescence resulted only from the nuclear
export of GFP fusion proteins and not from de novo protein
synthesis. Simultaneously, part of the cell samples were also treated
for 3 hours with 5 mg/ml actinomycin D (ActD), which is known
to specifically block the nuclear import of Rev protein by a
mechanism not yet elucidated [42]. The remaining cell samples
were treated with CHX, ActD and 20 ng/ml of leptomycin B for
3 hours. The subcellular localization of each GFP fusion protein
was determined in at least 200 cells per experimental condition
from three independent experiments.
Fluorescence microscopy
Endogenous Atx3 was detected, by immunocytochemistry, with
anti-MJD antibody (1:10000), kindly provided by H. Paulson, and
visualized using a secondary antibody labeled with Alexa 488
(1:1000, Invitrogen). For fluorescence analysis of GFP fusion
proteins, cells were washed with phosphate-buffered saline (PBS),
fixed with 4% paraformaldehyde: 4% sacarose for 15 min, and
rinsed with PBS. The coverslips were then inverted and mounted
on glass slides with Vectashield mounting medium (Vector
Laboratories). The cell nucleus was stained with Hoescht 33342
(0,5 mg/ml, Molecular Probes). Fluorescence observations were
performed using a Zeiss Axiovert 200 fluorescence microscope,
coupled to a digital photographic camera (Axiocam HRM).
Confocal microscopy was performed using a Zeiss LSM 510 Meta
system.
Results and Discussion
Ataxin-3 has a mixed cytoplasmic and nuclear
distribution
Ataxin-3 is an ubiquitous protein that is found both in the
cytoplasm [44] and in the nucleus [5,7]. However, upon expansion
of the polyQ tract the protein forms insoluble inclusions
predominantly located inside the nucleus of the affected cells [6].
Interestingly, the localization of the protein inside the cell is
critically dependent on the cell type [5,7]. Immunostaining of
HEK293T cells with an anti-Atx3 antibody (kindly provided by H.
Paulson [6]) showed that endogenous Atx3 is predominantly
located in the nucleus (Fig. 1a), while its distribution is more
homogeneous in COS-7 cells (Fig. 1c). Interestingly, when both
cell lines were transiently transfected with Atx3 N-terminally
tagged with GFP (GFP-Atx3 (28Q), Figs. 1e and 1g), Atx3 was
found predominantly in the cytoplasm of both cell types, in
agreement with previous data [5,6,45].
In order to determine whether Atx3 can be actively transported
across the nuclear membrane we analyzed the effect of leptomycin
B, a specific covalent inhibitor of the nuclear export factor
CRM1/exportin [46,47], on the subcellular distribution of both
endogenous and overexpressed Atx3 in HEK293 and COS-7 cell
lines. In eukaryotic cells, nuclear export of proteins is frequently
mediated by this nuclear export factor, which binds to nuclear
export signals (NES) on cargo molecules. If Atx3 is a nuclear
shuttling protein, interfering with its putative nuclear export would
be expected to modify Atx3 subcellular localization by increasing
the proportion of the protein localized in the nucleus. Indeed, after
cell treatment with leptomycin B both endogenous Atx3 (Figs. 1b
and f) and transfected GFP-Atx3 (28Q) (Figs. 1d, h) accumulate in
the nucleus of a subpopulation of cells, suggesting that Atx3 exits
the cell nucleus by active transport at least partially dependent on
the CRM1/exportin pathway. In COS-7 cells the nuclear
accumulation of GFP-Atx3(28Q) could be observed in
26.564.5% of cells after leptomycin B treatment, whereas in
untreated cells only 4.862.4% of cells showed nuclear accumu-
lation of the protein. Nuclear export dependent on CRM1
receptor has also been demonstrated for other proteins containing
expandable polyglutamine tracts such as ataxin-7 [32] and
huntingtin [33]. In agreement with what is observed for Atx3 in
the context of the full-length protein, leptomycin B treatment of
cultured cells tranfected with huntingtin lead to a partial nuclear
accumulation of the protein corresponding to a 10% increase in
nuclear fluorescence of huntingtin [33].
Ataxin-3 contains a functional nuclear localization signal
Translocation of macromolecules larger than 40–60 kDa in and
out of the nucleus is an active, energy-dependent process that is
mediated by specific sequence motifs: nuclear localization signals
(NLS) and nuclear export signals (NES). ‘‘Classical’’ examples of
NLSs are the highly basic motifs originally found in the simian
virus 40 (SV40) large T antigen and in nucleoplasmin, although
several sequences differing from those basic ones have also been
shown to function as NLS [48,49,50]. In ‘‘classical’’ nuclear
import, importin-a recognizes and binds the target proteins in the
cytoplasm, mediating their transport across the nuclear pore
complex after formation of a ternary complex with importin-b
[48], although some NLS-containing cargoes can be directly
recognized by importin-b without the need of the adaptor protein.
Within importin-a, the major NLS binding pocket contains a
series of negatively charged residues that form salt bridges with the
basic residues within the NLS sequences [51]. A putative NLS has
been identified within the amino acid sequence of Atx3 [5], which
is conserved among Atx3 proteins from diverse species (Fig. 2).
In order to test the functionality of the identified NLS sequence,
we used a pNIA vector-based genetic one-hybrid system that
allows identification of nuclear proteins in yeast cells [39]. This
assay is based on the functional outcome of the nuclear import of
the tested protein, which, if it reaches the yeast cell nucleus, allows
specific induction of a reporter gene. The advantage of this
approach is allowing the quantitative evaluation of the strength of
the nucleocytoplasmic shuttling signals, independently of the
cellular model. This system has been consistently used for
mutational analysis of nuclear proteins to delineate and charac-
terize the NLS [52] and for testing the integrity of the nuclear pore
complex permeability barrier [53]. The rationale for this assay is
the expression in the yeast S. cerevisiae cells of the test protein fused
to a modified LexA DNA binding domain (DBD) and the Gal4
transcriptional activation domain (AD). This transcription based
assay relies on the ability of a functional NLS to allow the chimera
to enter the yeast nucleus and activate transcription of a LexA
responsive b-galactosidase or HIS3 reporter gene. In the absence
of a functional NLS, the fusion protein is not efficiently imported
into the nucleus, and is unable to activate transcription. As a result,
this assay provides a simple measure of NLS function based either
Ataxin-3 Nuclear Shuttling
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the qualitative analysis of yeast growth in a medium lacking
histidine. This system is not limited to the identification of yeast
NLSs, as the nuclear import apparatus is highly conserved
between yeast and higher eukaryotic cells [49,50].
pNIA-GFP and pNIA-SV40NLS were used as controls for the
nuclear import assay. pNIA-GFP encodes the fusion protein
mLexA-Gal4AD-GFP and was used as negative control because it
is not imported into the nucleus, resulting in minimal expression of
the two reporter genes, whereas pNIA-SV40NLS encodes the
fusion protein mLexA-SV40NLS-Gal4AD-GFP which, due to the
presence of the SV40NLS, is actively imported into the nucleus,
leading to high activity of both lacZ and HIS3 genes. The cDNA
for ataxin-3 (with 28 glutamines) was cloned in the pNIA vector,
and to ensure that the resulting fusion protein had a molecular
weight not compatible with simple diffusion across the nuclear
pore, GFP was inserted between Gal4AD and Atx3. When
expressed in yeast, the pNIA-GFP-Atx3 fusion protein induced
growth on histidine-deficient medium (data not shown), suggesting
that Atx3 was actively imported into the nucleus. To confirm this
Figure 1. Ataxin-3 can shuttle between the nucleus and the cytoplasm. Endogenous Atx3 in HEK293T (a, b) and COS-7 (c, d) cell lines was
detected by immunocytochemistry, using an anti-Atx3 antibody. Subconfluent cultures of HEK293 (e, f) and COS-7 cells (g, h) were transiently
transfected with the plasmids encoding GFP-Atx3(28Q), and the localization of the fusion protein was detected by the GFP fluorescence. To explore
the possibility of CRM1-mediated nuclear export of endogenous (b, d) or overexpressed (f, h) Atx3, cells were incubated with 20 gg/ml of Leptomycin
B (LMB), for 3 hours, prior to fixation. The subcellular localization of Atx3 was visualized by fluorescence microscopy.
doi:10.1371/journal.pone.0005834.g001
Figure 2. Human ataxin-3 and its closest homologues contain conserved nuclear import sequences. Sequence alignment of human (H.
sapiens), wild boar (S. scrofa), mouse (M. musculus), rat (R. norvegicus), and chicken (G. gallus) ataxin-3. Identical residues are shown in white against a
red background; conserved residues are shown in red. The conserved NLS sequence is highlighted by blue triangles below the alignment; the tested
hydrophobic putative NES sequences are indicated by blue stars. The Josephin domain (JD) corresponds to residues 1 to 182, the UIM1 to residues
225 to 240 and the UIM2 to residues 246 to 259. The figure was prepared with ESPript [68].
doi:10.1371/journal.pone.0005834.g002
Ataxin-3 Nuclear Shuttling
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culture of yeast cells expressing the different constructs (Fig. 3).
The results obtained show that pNIA-GFPAtx3 induced levels of
b-galactosidase activity significantly higher than the levels
obtained for pNIA-GFP, a finding which confirms that Atx3 is
actively imported into the nucleus of yeast cells.
To determine whether the proposed NLS of Atx3 was indeed
responsible for the translocation of the fusion protein into the
nucleus of yeast cells, we mutated the conserved arginine residue
within the putative NLS sequence into a threonine residue (pNIA-
GFP-Atx3R282T). This mutation is a typical mutation performed
in the analysis of conserved NLS sequences since it changes a basic
residue for a neutral residue without modifying its polar character
[28], and has also been shown to disrupt the function of the NLS
identified in ataxin-1 and ataxin-7 [28,30]. As shown in Figure 3,
the mutation results in the reduction the b-galactosidase activity to
levels similar to the negative control (pNIA-GFP), indicating that
the mutation greatly impairs Atx3 nuclear import in yeast. The
mutation of the same arginine residue to an alanine residue (pNIA-
GFP-Atx3R282A) was also tested, and resulted in a reduction on
the nuclear accumulation of the fusion protein (Fig. 3). These data
show that interference with the putative NLS disrupts the nuclear
import ability of Atx3.
The nuclear import activity of Atx3 was further confirmed in
mammalian cells by comparing the subcellular localization of
GFP-Atx3(28Q)R282T with GFP-Atx3(28Q) (Fig. 4). When
transfected in COS-7 cells, both constructs localized mainly in
the cytoplasm of the cells. Because our data show that Atx3 can
also be exported from the nucleus and that this export is at least
partially mediated by the CRM1 pathway (see above), the similar
localization of wild-type Atx3 and the R282T mutant might be
due to the presence of competitive nuclear export signals.
Therefore, in order to investigate if there is a difference between
the nuclear shuttling ability of the wild-type protein and the
R232T mutant in COS-7 cells, we incubated the cells with
leptomycin B, thereby at least partially inhibiting nuclear export,
and determined their subcellular re-localization. As shown in Fig. 1
(panels g and h), GFP-Atx3(28Q) accumulates in the nucleus of a
subpopulation of cells in the presence of leptomycin B. When
GFP-Atx3(28Q)R282T is expressed in COS-7 cells this nuclear
accumulation is not observed (Fig. 4), indicating that the identified
NLS sequence is also responsible for driving Atx3 into the nucleus
of mammalian cells. Therefore, we conclude that Atx3 contains a
basic NLS sequence that is functional and promotes its active
import into the cell nucleus.
The nuclear export of ataxin-3 is mediated by CRM1-
dependent and -independent pathways
Since the nuclear export of Atx3 was partially inhibited in the
presence of leptomycin B (Figs. 1, 4), we analyzed the nuclear
export activity of Atx3 using the Rev(1.4)-GFP nuclear export
assay [42]. This assay is based on the expression of fusion proteins
consisting of Rev(1.4), an export-defective HIV-1 Rev protein
mutant, the sequence to be tested, and GFP. The nuclear export
functionality of the sequence to be tested is evaluated by analyzing
its capacity to promote nuclear export of the Rev(1.4)-GFP fusion
protein. The Rev(1.4)-GFP fusion protein, which was used as a
negative control for this assay, was localized exclusively in the
nucleus of COS-7 cells, presenting a clear nucleolar accumulation
(Fig. 5b). Rev(1.4)-NES–GFP, a fusion protein that contains the
Rev NES, which was used as a positive control for this assay, was
localized in the nucleus and the cytoplasm of transfected cells
(Fig. 5b). The number of cells presenting exclusively cytoplasmic
localization was enhanced following actinomycin D (ActD)
treatment (Fig. 5b), which blocks the nuclear import mediated
by the Rev NLS [42], whereas the cytoplasmic localization of
Rev(1.4)-NES-GFP was completely blocked by addition of
leptomycin B (Fig. 5b), as expected for a protein whose nuclear
export is dependent on CRM1.
Full-length Atx3 containing 28 glutamine residues [Atx3(28Q)],
when fused to Rev(1.4)-GFP, was driven into the nucleus, where it
formed punctuate structures resembling the insoluble nuclear
inclusions (Fig. 5b). The morphology of these structures is clearly
distinct from the nucleolar accumulation of fluorescence observed
for Rev(1.4)-GFP (Fig. 5b). We also tested full-length Atx3
containing 84 glutamine residues [Atx3(84Q), Fig. 5b], which
formed punctuate structures, presumably aggregates, in the
nucleus of transfected cells. These structures were not sensitive
to the blockade of nuclear import of the Rev fusion protein using
ActD. In fact, this result is in agreement with previous observations
that Atx3 has a tendency to oligomerize independently of the
expanded polyQ tract [54,55,56] and that the nuclear environ-
ment promotes protein misfolding and aggregation [57]. Curious-
ly, it was observed that overexpression of ataxin-7 in cell culture
models induced the nuclear localization of the protein and
formation of large protein ‘‘accumulations’’ in ,30% of the cells,
independently of the polyglutamine tract size [30].
The nuclear aggregation of full-length Atx3 when fused to
Rev(1.4)-GFP, independently of the extent of the polyQ tract,
presumably triggered by the strong Rev NLS, hampered the
investigation of the nuclear export activity of full-length Atx3 using
this system. Therefore, we prepared constructs encoding various
domains of Atx3 fused to Rev(1.4)-GFP, all lacking the
polyglutamine tract and the endogenous NLS (Fig. 5a). The
fusion protein consisting of the Josephin domain of Atx3 [JD-(1–
182)] fused to Rev(1.4)-GFP showed a distribution between the cell
nucleus and cytoplasm in 46% of the cells after cell treatment with
ActD (Fig. 5b). We also tested the cellular localization of the fusion
Figure 3. Evaluation of the nuclear import capacity of ataxin-3
protein in yeast. The b-galactosidase activity was quantified in liquid
cultures after yeast cell growth in minimal medium lacking tryptophan.
The data are expressed as a percentage of the enzymatic activity
obtained for yeast cultures transformed with pNIA-SV40NLS; standard
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of Atx3 that contains the UIMs [Atx3(1–263)], fused to Rev(1.4)-
GFP [Rev1.4-Atx3(1–263)-GFP]. This protein also displayed a
nuclear and cytoplasmic localization, and the number of cells
showing a mixed distribution of the protein increased to 78% after
cell treatment with ActD (Fig. 5b). The nuclear export activities of
JD(1–182) and Atx3(1–263) were not inhibited by the CRM1
export inhibitor leptomycin B (+LMB).
These results suggest that the Josephin domain can mediate the
nuclear export of the fusion proteins, which requires the context of
the Josephin domain plus a sequence downstream this catalytic
region. However, this UIM-containing segment alone [Rev(1.4)-
Atx3(183–263)-GFP, Fig. 5b] was not sufficient to promote
nuclear export of the fusion protein. Finally, we asked whether
the nuclear export of the Atx3(1–263) fragment was dependent on
the ubiquitin binding capacity of its UIMs. It has been shown, in a
cell-based assay of polyQ aggregation, that recruitment of non-
expanded Atx3 into nuclear aggregates is mediated by its UIMs
[58]. Therefore, we mutated the two UIMs in the Atx3(1–263)
fragment in order to compromise their functionality [Atx3(1–
263)(S236A,S256A)]. This protein had the same pattern of cellular
distribution as the wild-type Atx3(1–263) fragment (Fig. 5b),
indicating that functionality of the UIMs is not required for the
increased nuclear export activity observed for this region of Atx3.
Our results clearly demonstrate that nuclear export of Atx3 is
dependent on a complex Atx3 motif, located in the N-terminal
portion of the protein, which requires the context of the Josephin
domain plus the ubiquitin-interacting motifs. Taken together,
these data indicate either that nuclear export of Atx3 is mediated
by a nuclear export receptor that recognizes a properly folded
conformational motif and/or that multiple export pathways
contribute to the overall nuclear export of full-length Atx3.
Interestingly, a nuclear export receptor, exportin 7, has been
recently described, which recognizes nuclear export signals that
include conformation-dependent recognition motifs, rather than
short linear sequences [59].
Since we observed nuclear accumulation of Atx3 in a
population of COS-7 cells when the CRM1 transporter was
inhibited with leptomycin B (Figs. 1 and 4), we looked for leucine-
rich nuclear export signal (NES) sequences within Atx3 primary
structure that might match the consensus NES sequence for the
CRM1-dependent export [60], using the NetNES predictor
(http://www.cbs.dtu.dk/databases/NESbase-1.0 [43]). We found
6 putative NES sequences, of which 4 are present within the
Josephin domain (Fig. 2, NES1-NES4), one is located between the
Josephin domain and the first ubiquitin interaction domain (NES5)
and the last one (NES6) corresponds to the first ubiquitin
interaction motif of the protein (Fig. 2). We have fused the
putative NESs identified in Atx3 with Rev(1.4)-GFP, and tested
whether the presence of these sequences can induce the
translocation of Rev(1.4)-GFP from the cell nucleus. However,
the isolated NES sequences failed to induce nuclear export when
inserted into the Rev(1.4)-GFP vector (Table 1). The observation
that in this system none of the tested sequences showed nuclear
export activity can result from the fact that these sequences do not
function as active leucine-rich nuclear export signals, but could
also be a consequence of testing the sequences isolated from their
overall protein context. For example, the isolated NES of Rev
binds to CRM1 much more weakly than does the full-length Rev
protein [61], implying that an NES may require flanking
sequences to adopt the conformation needed for CRM1 binding.
Another possibility is that each isolated sequence is not strong
enough to drive detectable nuclear export of Rev1.4-GFP, which
has a very strong NLS, and that several NESs work in concert to
achieve efficient export of Atx3. In fact, recent studies show that
most NESs bind to CRM1 with relatively low affinity, since high-
affinity NES binding to CRM1 impairs the efficient release of
export complexes from the nuclear pore complex [60].
The nuclear export of GFP-Atx3(28Q) was partially inhibited
by leptomycin B (Figs. 1, 4), suggesting that a CRM1-dependent
pathway is involved in the nuclear export of Atx3. On the other
hand, using the Rev(1.4)-GFP fusion system, which contains a
strong NLS, we detected nuclear export activity of the N-terminal
portion of Atx3 (Josephin domain and UIMs) that was not sensitive
to leptomycin B (Fig. 5b). This supports the possibility that, in
resemblance to what has been found for huntingtin [33,34],
CRM1-dependent and -independent nuclear export mechanisms
coexist to cooperate in determining the subcellular distribution of
Figure 4. Evaluation of the nuclear import ability of ataxin-3 in mammalian cells. COS-7 cells expressing either GFP-Atx3(28Q), or GFP-
Atx3(28Q)R282T, were analyzed by confocal fluorescence microscopy 48 h postransfection. GFP-Atx3(28Q) and GFP-Atx3(28Q)R282T are
predominantly localized in the cytoplasm. Although the incubation with LMB (20 ng/ml, 3 h) lead to nuclear accumulation of GFP-Atx3(28Q), in
26.564.5% of the cells, LMB had no effect on GFP-Atx3(28Q)R282T subcellular localization. The cell nucleus was stained with Hoechst 33342.
doi:10.1371/journal.pone.0005834.g004
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pathways may be dominant when compared to the other. Similar
to that of Atx3 and huntingtin, the nuclear export of other
proteins, such as a-catenin [62], receptor-interacting protein 3
(RIP3) [63] and the African Swine Fever Virus p37 protein [64],
has been shown to be mediated by both CRM1-dependent and –
independent pathways.
Conclusion
A correlation between the nuclear environment and protein
aggregation in MJD models has been pinpointed by studies using
Atx3 with an exogenously added NLS that demonstrated in situ
that the nuclear environment drives aggregation of both expanded
and non-expanded Atx3 [57,65]. Recent in vivo studies have shown
that adding an exogenous NES does not only suppress the
formation of NIIs almost completely, but also seems to prevent the
aggregation of Atx3 [35]. Furthermore, live-cell imaging studies
showed that expanded polyQ tracts slow the dynamics of intact
Atx3, and that the export of expanded Atx3 is less efficient than
the export of normal Atx3 [66], suggesting a defect on the
nucleocytoplasmic shuttling activity of the expanded protein. In
fact, a recent study using a Drosophila system to screen for genetic
modifiers of Atx3 neurodegeneration identified as a suppressor of
Atx3-mediated toxicity, among others, the gene encoding the
nuclear export protein Embargoed, the orthologue of human
CRM1 [67]. In order to further understand the link between
nuclear localization, aggregation and toxicity of expanded Atx3, it
is essential to identify the mechanisms behind the intracellular
dynamics of the normal protein. In this study, we have confirmed
the functionality of the putative Atx3 NLS in yeast and
mammalian cells, and detected CRM1-dependent and –indepen-
dent pathways that mediate the nuclear export of Atx3. Our data
show that the CRM1-independent nuclear export of Atx3 is
mediated by the N-terminal region of the protein and is critically
dependent on a three-dimensional motif whose integrity is
compromised when the Josephin domain is physically separated
from the UIMs. Future identification of the nuclear transporter(s)
responsible for this pathway, will pave the way to determining how
the subcellular localization of Atx3 is regulated in physiological or
pathological conditions.
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